News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
459,219 Results
Type
Article (24153)
Company Profile (156)
Press Release (434910)
Multimedia
Podcasts (77)
Webinars (11)
Section
Business (145061)
Career Advice (1325)
Deals (25968)
Drug Delivery (103)
Drug Development (54789)
Employer Resources (99)
FDA (10080)
Job Trends (11174)
News (242295)
Policy (23662)
Tag
Academia (1394)
Accelerated approval (3)
Adcomms (22)
Allergies (56)
Alliances (38852)
ALS (57)
Alzheimer's disease (807)
Antibody-drug conjugate (ADC) (103)
Approvals (10089)
Artificial intelligence (198)
Autoimmune disease (16)
Automation (9)
Bankruptcy (237)
Best Places to Work (8570)
BIOSECURE Act (18)
Biosimilars (106)
Biotechnology (69)
Bladder cancer (53)
Brain cancer (20)
Breast cancer (154)
Cancer (1430)
Cardiovascular disease (136)
Career advice (1091)
Career pathing (23)
CAR-T (83)
Cell therapy (233)
Cervical cancer (14)
Clinical research (45594)
Collaboration (610)
Compensation (360)
Complete response letters (23)
COVID-19 (1671)
CRISPR (29)
C-suite (189)
Cystic fibrosis (61)
Data (1420)
Decentralized trials (2)
Denatured (20)
Depression (33)
Diabetes (164)
Diagnostics (4158)
Digital health (11)
Diversity (9)
Diversity, equity & inclusion (25)
Drug discovery (92)
Drug pricing (120)
Drug shortages (31)
Duchenne muscular dystrophy (64)
Earnings (53256)
Editorial (38)
Employer branding (15)
Employer resources (90)
Events (64561)
Executive appointments (593)
FDA (10913)
Friedreich's ataxia (3)
Frontotemporal dementia (1)
Funding (441)
Gene editing (60)
Generative AI (20)
Gene therapy (182)
GLP-1 (643)
Government (3384)
Grass and pollen (5)
Guidances (47)
Healthcare (12258)
Huntington's disease (13)
IgA nephropathy (21)
Immunology and inflammation (95)
Indications (24)
Infectious disease (1781)
Inflammatory bowel disease (100)
Inflation Reduction Act (8)
Influenza (38)
Intellectual property (70)
Interviews (195)
IPO (10666)
IRA (47)
Job creations (2921)
Job search strategy (955)
Kidney cancer (7)
Labor market (27)
Layoffs (330)
Leadership (17)
Legal (5630)
Liver cancer (40)
Lung cancer (209)
Lymphoma (108)
Machine learning (3)
Management (35)
Manufacturing (270)
MASH (54)
Medical device (6318)
Medtech (6321)
Mergers & acquisitions (15709)
Metabolic disorders (548)
Multiple sclerosis (57)
NASH (20)
Neurodegenerative disease (58)
Neuropsychiatric disorders (24)
Neuroscience (1181)
NextGen: Class of 2025 (4556)
Non-profit (2901)
Now hiring (23)
Obesity (333)
Opinion (209)
Ovarian cancer (41)
Pain (75)
Pancreatic cancer (49)
Parkinson's disease (101)
Partnered (16)
Patents (171)
Patient recruitment (60)
Peanut (24)
People (44882)
Pharmaceutical (79)
Pharmacy benefit managers (21)
Phase I (14156)
Phase II (19418)
Phase III (15516)
Pipeline (951)
Policy (155)
Postmarket research (1773)
Preclinical (5111)
Press Release (70)
Prostate cancer (77)
Psychedelics (24)
Radiopharmaceuticals (183)
Rare diseases (276)
Real estate (4776)
Recruiting (38)
Regulatory (16231)
Reports (24)
Research institute (1302)
Resumes & cover letters (209)
Rett syndrome (1)
RNA editing (2)
RSV (29)
Schizophrenia (66)
Series A (69)
Series B (43)
Service/supplier (17)
Sickle cell disease (42)
Special edition (16)
Spinal muscular atrophy (117)
Sponsored (21)
Startups (2495)
State (2)
Stomach cancer (9)
Supply chain (65)
Tariffs (46)
The Weekly (55)
Vaccines (412)
Venture capitalists (31)
Weight loss (253)
Women's health (22)
Worklife (11)
Date
Last 7 days (542)
Last 30 days (1536)
Last 365 days (21561)
2025 (7141)
2024 (23132)
2023 (26053)
2022 (34789)
2021 (37284)
2020 (36951)
2019 (33181)
2018 (25475)
2017 (22728)
2016 (21711)
2015 (24934)
2014 (19367)
2013 (16396)
2012 (17758)
2011 (18357)
2010 (16660)
Location
Africa (542)
Alabama (31)
Alaska (5)
Arizona (115)
Arkansas (10)
Asia (29734)
Australia (3963)
California (3462)
Canada (1557)
China (389)
Colorado (178)
Connecticut (166)
Delaware (106)
Europe (63801)
Florida (584)
Georgia (95)
Hawaii (1)
Idaho (33)
Illinois (403)
India (23)
Indiana (229)
Iowa (6)
Japan (136)
Kansas (77)
Kentucky (22)
Louisiana (7)
Maine (27)
Maryland (631)
Massachusetts (2727)
Michigan (119)
Minnesota (204)
Mississippi (2)
Missouri (47)
Montana (18)
Nebraska (16)
Nevada (35)
New Hampshire (28)
New Jersey (1343)
New Mexico (24)
New York (985)
North Carolina (719)
North Dakota (5)
Northern California (1451)
Ohio (148)
Oklahoma (10)
Oregon (24)
Pennsylvania (887)
Puerto Rico (12)
Rhode Island (23)
South America (804)
South Carolina (5)
Southern California (1382)
Tennessee (73)
Texas (544)
United States (14301)
Utah (86)
Virginia (116)
Washington D.C. (58)
Washington State (301)
West Virginia (3)
Wisconsin (39)
459,219 Results for "johnson matthey pharma services".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Compensation
Top 6 Highest-Paid Pharma CEOs in 2024
Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.
April 16, 2025
·
7 min read
·
Annalee Armstrong
Johnson Matthey signs agreement to sell its Medical Device Components business for US$700m
Johnson Matthey Plc (JM) announces that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.
March 20, 2024
·
4 min read
Earnings
Amgen Advocates For ‘Pro-Growth Tax Policy’ Instead of Tariffs to Boost Domestic Manufacturing
Like fellow Big Pharmas Eli Lilly and Johnson & Johnson, Amgen is urging the Trump administration to consider tax policy instead of tariffs to promote domestic pharma manufacturing.
May 2, 2025
·
2 min read
·
Tristan Manalac
Manufacturing
J&J Joins Pharma Peers With $55B US Manufacturing Boost Following Trump’s Tariff Threats
Johnson & Johnson follows Eli Lilly in spending billions on U.S. manufacturing after President Donald Trump threatened major tariffs on pharmaceutical products. Pfizer has also promised a similar commitment.
March 21, 2025
·
2 min read
·
Annalee Armstrong
Business
New Jersey’s Life Sciences Scene Continues Expanding Beyond Big Pharma
Known as the home of big-name companies including Johnson & Johnson, New Jersey has become a destination for more and more small and midsize life sciences businesses. Choose New Jersey, Grace Therapeutics and Onyx Equities executives discuss the state’s life sciences scene.
April 10, 2025
·
6 min read
·
Angela Gabriel
Press Releases
Johnson & Johnson’s TAR-200 monotherapy demonstrates highest complete response rate reported to date with sustained clinical benefits in patients with certain types of bladder cancer
April 28, 2025
·
11 min read
Press Releases
Johnson & Johnson to Present New Data for TECNIS Odyssey, The Fastest Growing PCIOL in the U.S^, at ASCRS 2025
April 28, 2025
·
9 min read
Press Releases
Johnson & Johnson Reports Q1 2025 Results
April 15, 2025
·
23 min read
Press Releases
TREMFYA® (guselkumab) receives European Commission approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson’s leadership in inflammatory bowel disease
April 25, 2025
·
14 min read
Business
Five Biggest Drug Face-Offs in Pharma History
Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of rivalry that includes blockbuster drugs Keytruda, Humira and Eliquis.
April 9, 2025
·
9 min read
·
Tristan Manalac
1 of 45,922
Next
